Human apolipoprotein A5 (Apo-A5) ELISA Kit

Code CSB-E11901h
Size 96T,5×96T,10×96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* Sample kit cost can be deducted as a $30 credit for each 96-assay kit of the same analyte and brand you subsequently purchase in six months till depleted. Apply now

Product Details

Alternative Names
Apo-AV ELISA Kit; ApoA-V ELISA Kit; Apoa5 ELISA Kit; APOA5_HUMAN ELISA Kit; ApoAV ELISA Kit; Apolipoprotein A-V ELISA Kit; Apolipoprotein A5 ELISA Kit; RAP3 ELISA Kit; Regeneration associated protein 3 ELISA Kit; Regeneration-associated protein 3 ELISA Kit
Abbreviation
Uniprot No.
Species
Homo sapiens (Human)
Sample Types
serum, plasma, tissue homogenates
Detection Range
2.5 ng/ml-40 ng/ml.
Sensitivity
1.25ng/ml.
Assay Time
1-5h
Sample Volume
50-100ul
Detection Wavelength
450 nm
Research Area
Cancer
Assay Principle
quantitative
Measurement
Competitive
Troubleshooting
and FAQs
Storage
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx
Description

The human APOA5 ELISA Kit is intended to measure human APOA5 in serum, plasma, or tissue homogenates. This assay employs the competitive inhibition enzyme immunoassay technique and enzyme-substrate chromogenic reaction to quantify human APOA5 concentration. The intensity of the colored product is negatively proportional to the concentration of APOA5 present in the sample. This human APOA5 ELISA kit has high specificity and excellent sensitivity.

APOA5 is synthesized and secreted exclusively by the liver and is present in plasma associated with chylomicrons, very low-density lipoprotein (VLDL), and high-density lipoprotein (HDL). It plays an important role in lipid metabolism, specifically in triglyceride (TG) and TG-rich lipoproteins (TRLs) metabolism. Abnormalities in the plasma concentration or structure of APOA5 are linked to hypertriglyceridemia, hyperchylomicronemia, myocardial infarction risk, obesity, and coronary artery disease.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
(From Uniprot)
Minor apolipoprotein mainly associated with HDL and to a lesser extent with VLDL. May also be associated with chylomicrons. Important determinant of plasma triglyceride (TG) levels by both being a potent stimulator of apo-CII lipoprotein lipase (LPL) TG hydrolysis and an inhibitor of the hepatic VLDL-TG production rate (without affecting the VLDL-apoB production rate). Activates poorly lecithin:cholesterol acyltransferase (LCAT) and does not enhance efflux of cholesterol from macrophages. Binds heparin.
Gene References into Functions
  1. Suggest that APOA5 SNPs rs10750097(G/G), rs1263173(A/A), rs17120035(T/T), and rs662799(G/G) may be associated with NAFLD. PMID: 29735301
  2. Evidence has established the association between the presence of APOA5 gene SNPs and the risk for obesity. (Review) PMID: 30053818
  3. Polymorphisms of the genes MTHFR (rs1801133) and APOA5 (rs662799), as well as anemia, are independent risk factors for stroke in Mexicans, together with traditional cardiovascular risk factors such as high triglycerides and high blood pressure. PMID: 29398535
  4. Different linkage disequilibrium was found betweenAPOA5 rs207560 and rs3135506 variants in Roma compared to Hungarians PMID: 28102463
  5. APOA5 polymorphisms rs662799 and rs3135507, with the CC and the AA genotypes, respectively, are associated with increased levels of both high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) in the Turkish Cypriot population. PMID: 29264753
  6. rs670, rs2854116, and rs662799 single nucleotide polymorphisms of the APOA1-C3-A5 cluster are associated with ischemic stroke in the northern Chinese Han population. PMID: 28635360
  7. The minor allele rs662799 in APOA5 was risk factor for coronary artery disease occurrence in the Chinese Han population. PMID: 29310573
  8. Heterozygous carriers of the variants of APOA5 display more pronounced post-prandial lipemia after pure fat load than wild-type carriers. PMID: 28730827
  9. Review/Meta-analysis: significant association of APOA5 rs662799 CC and APOA5 rs3135506 CG with increased risk of ischemic stroke. PMID: 28865324
  10. The data clearly show that the Arg282Ser mutation in APOA5 gene determines a reduction of triglycerides, total and LDL-cholesterol and apolipoprotein A-V levels in overweight/obese children and adolescents, demonstrating that this mutation has the power to affect lipid levels already since childhood. PMID: 28927406
  11. First study reporting the association of APOA5 gene variants with Metabolic Syndrome in Tunisia. This study emphasizes the role of APOA5 variants in the regulation of the triglycerides blood levels. PMID: 28624160
  12. that apos involved in TG metabolism such as apoC2, C3, E, and A4 (micromolar concentration), and apoB48 and apoA5 (single-digit nanomolar concentration) can be quantified from a single digestion mixture. PMID: 24694356
  13. APOA5 variants cause Hypertriglyceridemia. In high Cardiovascular risk patients APOA5 variants elevate triglyceride levels and shift the entire lipoprotein subclass distribution toward Atherogenic Dyslipidemia. PMID: 28500476
  14. Triglyceride-raising variant alleles of the APOA5 encoding apo A-V, associated with clinical Cardiovascular endpoints. PMID: 28534127
  15. Hypertriglyceridemic patients carrying the APOA5 -1131T>C polymorphism exhibited increased atherogenic LDL levels and arterial stiffness, probably due to an effect of the -1131T>C polymorphism on apoA5 concentrations PMID: 29211729
  16. The minor alleles of rs662799 (APOA5) and rs5072 (APOA1) modulate TG levels in Mexican children PMID: 27171122
  17. Rare variants in LPL and a common variant in APOA5 were more commonly found in Thai subjects with severe hypertriglyceridemia PMID: 27206937
  18. Collectively, these data demonstrate that APOA5 SNP rs651821 might be an important host genetic factor in determining the abundances of the health-promoting Bifidobacterium bacteria and the taxa to which this genus belongs. PMID: 27053630
  19. Data suggest that estrogen up-regulates serum concentrations of APOA5 and subsequently decreases serum triglyceride levels; APOA5 levels are higher in woman than in men, and the negative relationship between APOA5 and serum triglyceride levels is more significant in woman. PMID: 28376804
  20. Methylation in exon 3 of APOA5 and epigenetic variability are associated with high circulating triacylglycerol levels. PMID: 27613158
  21. the lead variant was the rs1558861 [1.99 (1.73-2.30); p = 7.37 x 10(-22) ], residing on chromosome (chr) 11 at the apolipoprotein A-I/A-5 (APOA1/APOA5) locus PMID: 27599772
  22. The single nucleotide polymorphisms in lipoprotein lipase, ApoA5, and CETP were associated with serum triglycerides and HDL-cholesterol levels, but not with coronary artery disease in Pakistani population under study. PMID: 28143480
  23. ur data indicate that the APOA5 rs662799 polymorphism is associated with dyslipidemia and the severity of coronary heart disease in Chinese women. PMID: 27716220
  24. HBV inhibits ApoA5 expression at both the transcriptional and translational levels through its core gene PMID: 27724895
  25. Compared with APOA5 c.553 GG carriers, c.553T carriers displayed an increased risk of HTG in the Asian population, with an overall random effects OR of 3.55 (95% CI: 2.46-5.13) in the dominant model.Our results suggest that APOA5 c. 553T is an independent risk factor for HTG and increased triglyceride levels in the Asian population. PMID: 27813673
  26. Genetic polymorphisms of T-1131C APOA5 and ALOX5AP SG13S114 can be considered risk factors for the susceptibility to ischemic stroke in Morocco. PMID: 27350673
  27. Data show that polymorphisms of rs662799 and rs2266788 in APOA5 gene, rs320 in LPL gene and rs708272 in CETP gene had significant association with the effect of the lipid-lowering therapy via atorvastatin on ischemic stroke patients. PMID: 27415775
  28. In this study, we investigated the association between the ApoA5 -1131T>C and -12,238T>C polymorphic loci in Korean patients with metabolic syndrome PMID: 26760709
  29. Serum triglycerides and very low-density protein levels were significantly high in children and adolescents carrying the 19WW apoa5 genotype. PMID: 27051036
  30. meta-analysis provides substantial evidence that the APOA5 -1131T/C polymorphism might contribute to coronary artery disease development in the Chinese population PMID: 26505382
  31. The results of our meta-analysis point to a strong link between both APOA5 -1131T>C and APOC3 -455T>C polymorphisms and an increased risk ofcoronary heart disease . PMID: 26782469
  32. A potential role for APOA5 common variants and related haplotypes as risk factors for obesity. PMID: 26524954
  33. APOA5 rs2075291 could play an important role in triglyceride and HDL-C level in metabolic syndrome, while the association of APOA5 rs662799 polymorphism is still under debate. PMID: 26702748
  34. the TT genotype of APOA5 c.553G T may have an important role in Taiwanese patients with hypertriglyceridemia PMID: 25843152
  35. APOA5 rs662799 polymorphism has interactions with the environmental factors associated with metabolic syndrome X. PMID: 26824674
  36. APOA5 -1131 T > C and APOC3 -455 T > C SNPs may play potent roles in the development and progression of coronary heart disease. (Meta-analysis) PMID: 26387083
  37. Single nucleotide polymorphisms (Rs651821) of APOA5 protein did not increase the risk of CHD in the Chinese population. PMID: 26397108
  38. Both the case-control study and meta-analysis confirm a significant association between APOA5 rs662799 and coronary heart disease. The results suggest a male-specific association between the APOA5 rs662799 polymorphism and coronary heart disease. [meta-analysis] PMID: 26309253
  39. ApoA-V in neonates was unique in its serum concentration and in the association with lipoprotein profile PMID: 26350810
  40. The polymorphisms rs662799 near APOA5 and rs769450 in APOE had significant association with metabolic syndrome X and its components in Korean males. PMID: 26365620
  41. Dietary fat intake modifies the effect of APOA5 and LEPR polymorphisms on serum triglycerides, cholesterol levels and obesity in young subjects. PMID: 26365669
  42. No SNPs within the BUD13-APOA5 region were associated with effect on HDL-cholesterol reduction but did have an effect on triglyceride and LDL-cholesterol levels following statin therapy. PMID: 25900265
  43. Our data support the hypothesis that apoA5 promotes hepatic TG storage and therefore contributes to the pathogenesis of non-alcoholic fatty liver disease PMID: 25938357
  44. cross-sectional study revealed the essential roles of the polymorphisms and haplotypes of APOA5 in the dysregulations of triglyceride levels in Uyghur population, which is an admixture population of Caucasians and East Asians PMID: 25313938
  45. In a dyslipemic population, genetic variants of APOA5 modulate lipoprotein subclass distributions, inducing an atherogenic profile associated with IMT defined subclinical atherosclerosis. PMID: 25770687
  46. Suggest ApoA5 genetic polymorphisms are associated with susceptibility to steroid-induced osteonecrosis of femoral head in Chinese population. PMID: 25515090
  47. Results show that the USF1 and APOA5 polymorphisms are associated with Familial combined hyperlipidemia and that the S19W SNP in the APOA5 gene is associated to the disease independently of total cholesterol, triglycerides and body mass index. PMID: 25308402
  48. APOA5 variants were associated with dyslipidemia and obesity in Mexicans. PMID: 24886709
  49. remarkable association especially between the -1131C Apo A5 variant and increased tPA levels in asymptomatic dyslipidemic patients PMID: 24815086
  50. analysis of methylation patterns of the APOA1/C3/A4/A5 cluster that may be directly involved in the transcriptional regulation of this cluster, especially in liver PMID: 25463085

Show More

Hide All

Involvement in disease
Hypertriglyceridemia, familial (FHTR); Hyperlipoproteinemia 5 (HLPP5)
Subcellular Location
Secreted. Early endosome. Late endosome. Golgi apparatus, trans-Golgi network.
Protein Families
Apolipoprotein A1/A4/E family
Tissue Specificity
Liver and plasma.
Database Links

HGNC: 17288

OMIM: 144650

KEGG: hsa:116519

STRING: 9606.ENSP00000227665

UniGene: Hs.283923

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1